The abstract is read at the publisher; the summary is JClub's.
A single 225Ac-SADA pretargeted radioimmunotherapy cycle against GPA33+ colorectal cancer xenografts produced complete volumetric tumor responses in most mice and durable remission.
- Why it matters: Conventional GPA33 IgG-linked radioimmunotherapy is limited by toxicity, and avoiding normal gut uptake is critical for safer dosing.
- What they did: Mice received step #1 with GPA33-SADA (10 mg/kg IV) and 24 h later step #2 with [86Y]Y-ABD (9 nmole IV), with dosimetry from tissue counting and treatment using one cycle of 2 doses 7 days apart (74 kBq + 74 kBq of 225Ac).
- The result: Median survival improved significantly across sq SW1222, LS174T, LOVO, and intraperitoneal SW1222 models, with complete response confirmed histologically at 180 days and only transient reversible weight loss (<15%) plus minimal acute chemical toxicity within 30 days.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.